(Q33321322)

English

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

progesterone-receptor positive breast cancer

0 references

1 reference

based on heuristic

inferred from title

Diethelm Wallwiener

3

object named as

Diethelm Wallwiener

0 references

author name string

Ute E Krainick-Strobel

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Werner Lichtenegger

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Augustinus H Tulusan

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Fritz Jänicke

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Gunther Bastert

6

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Ludwig Kiesel

7

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Birgit Wackwitz

8

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Stefan Paepke

9

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

language of work or name

0 references

publication date

26 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2270851

28 July 2018

Aromatase inhibitors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2270851

28 July 2018

Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2270851

28 July 2018

Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2270851

28 July 2018

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-62

21 January 2018

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-62

21 January 2018

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-62

21 January 2018

Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-62

21 January 2018

What constitutes optimal care for older women with breast cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18302747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18302747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/18302747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18302747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly

1 reference

https://pubmed.ncbi.nlm.nih.gov/18302747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant endocrine therapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18302747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-8-62

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33321322&oldid=2195240402"